Pharmaceutical company Elan has forecast a ⁈150m-⁈175m full-year before-tax loss, excluding revenues from its suspended MS drug Tysabri..Revenue for the first three months of the year was $134.3m (⁈106m), ahead of analysts' forecasts of $127.1m (⁈100m).
Ireland On-Line